NCT06688058
A Trial to Evaluate Tolerability and Immunogenicity of V540D in Healthy Adults (V540D-004)
StatusActive, Not Recruiting
PhasePhase 1
SponsorMerck Sharp & Dohme LLC
Primary completion (estimated)
At risk: Primary completion moved 60 days later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 10 versions: 9 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 4 words
- Primary and study completion pushed from Nov 30, 2026 to Jan 29, 2027
- Minor Trial status: Recruiting to Active, Not Recruiting
- Site details revised at 4 of 4 sites
- Minor Site details revised at 3 of 4 sitesv8
- Minor Primary and study completion dates: Aug 20, 2027 to Nov 30, 2026v6
- Notable Primary and study completion dates: Feb 12, 2027 to Aug 20, 2027
- Study sites: 1 to 4
Show 3 earlier versionsHide 3 earlier versions
- Minor Primary and study completion dates: Jan 6, 2027 to Feb 12, 2027v4
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 1
- Start date changed from estimate of Dec 12, 2024 to Dec 20, 2024
- Notable Eligibility criteria expanded, about 19 wordsv2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Number of Participants Who Experience a Solicited Injection-Site Adverse Event (AE)
Timeframe: Up to approximately 6 months
Number of Participants Who Experience a Solicited Systemic AE
Timeframe: Up to approximately 6 months
Number of Participants Who Experience Immediate Reactions Occurring Within 30 Minutes After Any Vaccination
Timeframe: Up to approximately 6 months
Number of Participants Who Experience Unsolicited AEs
Timeframe: Up to approximately 7 months
Number of Participants Who Experience a Serious Adverse Event (SAE)
Timeframe: Up to approximately 18 months
Number of Participants Who Experience a Medically-Attended AE (MAAE)
Timeframe: Up to approximately 18 months
Number of Participants Who Experience an Event of Clinical Interest (ECI)
Timeframe: Up to approximately 18 months
Secondary (1)
Total Immunoglobulin G (IgG) Geometric Mean Ratios (GMRs) for anti-HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58
Arms and interventions
V540DExperimental
Participants will receive vaccinations with V540D.
GARDASIL®9Active comparator
Participants will receive vaccinations with GARDASIL®9.
Biologicals: V540D, GARDASIL®9
Sites
4 sites in 1 country